CAAS Capital Management’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-1,900
Closed -$264K 306
2024
Q1
$264K Sell
1,900
-9,700
-84% -$1.22M 0.02% 376
2023
Q4
$1.44M Buy
+11,600
New +$1.19M 0.15% 147
2023
Q2
Sell
-15,400
Closed -$1.79M 721
2023
Q1
$1.79M Sell
15,400
-52,600
-77% -$5.89M 0.1% 213
2022
Q4
$7.7M Hold
68,000
0.47% 67
2022
Q3
$5.48M Hold
68,000
0.26% 114
2022
Q2
$5.07M Hold
68,000
0.25% 101
2022
Q1
$8.7M Sell
68,000
-3,600
-5% -$394K 0.36% 89
2021
Q4
$9.61M Hold
71,600
0.23% 117
2021
Q3
$9.79M Hold
71,600
0.2% 117
2021
Q2
$7.64M Buy
+71,600
New +$6.88M 0.13% 180
2021
Q1
Sell
-3,200
Closed -$296K 1212
2020
Q4
$296K Hold
3,200
﹤0.01% 729
2020
Q3
$330K Hold
3,200
0.01% 411
2020
Q2
$324K Sell
3,200
-12,800
-80% -$1.14M 0.01% 344
2020
Q1
$1.08M Buy
+16,000
New +$996K 0.11% 129

Other funds holding DXCM

CAAS Capital Management's DXCM Position: Q2 2023 in Review

CAAS Capital Management sold out of DexCom (DXCM) in Q2 2023, closing a stake of 1,600 shares — an estimated $186K sold.

CAAS Capital Management first reported a position in DXCM in Q4 2020 and held it in 6 quarters. The position peaked at $5.82M in Q1 2021. 954 funds tracked by Wall St. Rank hold DXCM as of Q2 2023.

  • CAAS Capital Management reported no remaining DexCom position as of Q2 2023 after selling out during the quarter.
  • CAAS Capital Management sold 1,600 DexCom shares in Q2 2023, an estimated $186K.
  • CAAS Capital Management first reported a position in DexCom in Q4 2020 and held it in 6 quarters.
  • CAAS Capital Management's DexCom position peaked at $5.82M in Q1 2021.
  • 954 funds tracked by Wall St. Rank held DexCom as of Q2 2023.

Based on CAAS Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.